Cost effectiveness of guideline advice for children with asthma: A literature review

Pediatric Pulmonology

Volumn 34, Issue 6, 2002, Pages 442-454

  Feenstra, Talitha L ^a,b   Rutten van Mölken, Maureen P M H ^b   Jager, Johannes C ^a   Van Essen Zandvliet, Liesbeth E M ^c  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c Asthma Centre Heideheuvel   (Netherlands)

Author keywords

Asthma; Children; Cost effectiveness analysis; Costs; Guidelines; Systematic review

Indexed keywords

BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUTICASONE; SALBUTAMOL; SALMETEROL; STEROID;

ARTICLE; ASTHMA; CHILD; CHRONIC DISEASE; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; HUMAN; LONG TERM CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL;

ASTHMA; CHILD; COST-BENEFIT ANALYSIS; ENGLAND; HUMANS; NETHERLANDS; PRACTICE GUIDELINES; TIME FACTORS; UNITED STATES;

EID: 0036891497     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/ppul.10177     Document Type: Article

References (57)

1. Van Weel C. What our practices teach us. Br J Gen Pract 1993;42:206-209.
2. Polder JJ, Meerding WJ, Koopmanschap MA,Bonneux L. van der Maas PJ. Kosten Van Ziekte in Nederland 1994. Rotterdam: Department of Public Health, Erasmus University; 1997. p 178.
3. Meerding WJ, Bonneux L, Polder JJ, Koopmanschap MA, van der Maas PJ. Demographic and epidemiological determinants of healthcare costs in Netherlands: cost of illness study. Br Med J [Clin Res] 1998:317:111-115.
4. Rutten-van Mölken MPMH, Postma MJ, Joore MA, Van Genugten M, Leidl R, Jager JC. Current and future medical costs of asthma and chronic obstructive pulmonary disease in The Netherlands. Respir Med 1999;93:779-787.
5. Massie RJ, Mellis CM. The economic aspects of drug delivery in asthma. PharmacoEconomics 1997;11:398-407.
6. Mellis CM, Peat JK, Woolcock AJ. The cost of asthma: Can it be reduced? PharmacoEconomics 1993;3:205-219.
7. Rutten-van Mölken MPMH, Van Doorslaer EKA, Rutten FFH. Economic appraisal of asthma and COPD care: A literature review 1980-1991. Soc Sci Med 1992;35:161-175.
8. Van den Boom G. Early Detection and Medical Treatment of Asthma and COPD in General Practice. Ph.D. thesis. Nijmegen: Katholieke Universiteit Nijmegen; 2000. p 19-35.
9. Sullivan S, Elixhauser A, Buist AS, Luce BR, Eisenberg J, Weiss KB. National Asthma Education and Prevention Program Working Group report on the cost effectiveness of asthma care. Am J Respir Crit Care Med 1996;154:S84-S95.
10. O'Brien KP. Managed care and the treatment of asthma. J Asthma 1995;32:325-334.
11. Liljas B, Lahdensuo A. Is asthma self-management cost-effective? Patient Educ Counsel [Suppl] 1997;32:97-104.
12. Volmer T. Wirtschaftlichkeitsueberlegungen bei Patientenschulungen. Pneumologie 1997;51:850-857.
13. Rutten-van Mölken M. The cost of asthma and cost-effectiveness of inhaled corticosteroids. Eur Respir Rev 1997;7:329-332.
14. Davis R, McTavish D. Budesonide. An appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in asthma. PharmacoEconomics 1995;7:457-470.
15. Peters DH. Salmeterol: An appraisal of its quality of life benefits and potential pharmacoeconomic positioning in asthma. PharmacoEconomics 1995;7:572-574.
16. Dirksen WJ, Geyer RMM, de Haan M, Kolnaar BMG. NHG- Standaard astma bij kinderen. Huisarts Wetensch 1992;35:355-362.
17. Dirksen WJ, Geijer RMM, de Haan M, de Koning G, Flikweert S, Kolnaar BMG. NHG-Standaard astma bij kinderen, eerste herziening. Huisarts Wetensch 1998;41:130-143.
18. Hoekstra MO. Behandeling van astma bij kinderen; herziene richtlijnen van kinderlongartsen. Ned Tijdschr Geneeskd 1997;141:2223-2229.
19. National Institutes of Health. Guidelines for the Diagnosis and Management of Asthma. Expert Panel Report 2. Bethesda: National Institutes of Health. National Heart Lung and Blood Institute; 1997. NIH publication no. 97-4051. 146 p.
20. British Thoracic Society. The British guidelines on asthma management, 1995 review and position statement. Thorax [Suppl] 1997;52:1-21.
21. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. 2nd Ed. Oxford: Oxford University Press; 1997. p 272-284.
22. Goetzsche PC, Hammarquist C, Burr M. House dust mite control measures in the management of asthma: Meta-analysis. Br Med J [Clin Res] 1998;317:1105-1110.
23. Hammarquist C, Burr ML, Goetzsche PC. House dust mite control measures for asthma. Cochrane Database Syst Rev 2000. Issue 4.
24. Abramson MJ, Puy RM, Weiner JM. Allergen specific immunotherapy for asthma. Cochrane Database Syst Rev 1998. Issue 1.
25. Cates CJ, Jefferson TO, Bara AI. Influenza vaccination in asthma: Efficacy and side-effects. Cochrane Database Syst Rev 1999. Issue 4.
26. Bueving H, Thomas S, van der Wouden J, de Jongste J, van Suijlekom-Smit L, Osterhaus A, Pistoor F, Rimmelzwaan G, Rutten-van Mölken M. Influenza Vaccination in Asthmatic Children and Adolescents Trial. Lancet, Protocol Review: Protocol 00PRT/4 [web page]. Located at: http:www.thelancet.com. Accessed August 2001.
27. Calpin C, MacArthur C, Stephens D, Feldman W, Parkin PC. Effectiveness of prophylactic inhaled steroids in childhood asthma: A systemic review of the literature. J Allergy Clin Immunol 1997;100:452-457.
28. Walters EH, Walters J. Inhaled short-acting beta2-agonist use in asthma: Regular vs. as needed treatment. Cochrane Database Syst Rev 2000. Issue 4.
29. Ducharme FM, Hicks GC. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma. Cochrane Database Syst Rev 2000. Issue 4.
30. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). Br Med J [Clin Res] 2000;320:1368-1373.
31. Adams NP, Bestall JB, Jones PW. Inhaled beclomethasone versus placebo for chronic asthma. Cochrane Database Syst Rev 2000. Issue 4.
32. Sharek PJ, Bergman DA. Beclomethasone for asthma in children: Effects on linear growth. Cochrane Database Syst Rev 2000. Issue 4.
33. Rutten-van Mölken MPMH, van Doorslaer EKA, Jansen M, van Essen-Zandvliet E, Rutten F. Cost effectiveness of inhaled corticosteroid plus bronchodilator therapy versus bronchodilator monotherapy in children with asthma. PharmacoEconomics 1993;4:257-270.
34. Conett GJ, Lenney W, McConchie SM. The cost effectiveness of budesonide in severe asthmatics aged one to three years. Br J Med Econ 1993;6:127-134.
35. Gerdtham UG, Hertzman P, Joensson B, Boman G. Impact of inhaled corticosteroids on acute asthma hospitalization in Sweden: 1978 to 1991. Med Care 1996;34:1188-1198.
36. Stempel DA. Salmeterol/fluticasone propionate combination product in asthma. An evaluation of its cost effectiveness vs. fluticasone propionate. PharmacoEconomics [Suppl] 1999;16:1-34.
37. Booth PC, Wells NEJ, Morrison AK. A comparison of the cost effectiveness of alternative prophylactic therapies in childhood asthma. PharmacoEconomics 1996;10:262-268.
38. Andersson F, Kjellman M, Forsberg G, Moller C, Arheden L. Budesonide is more cost-effective than sodium cromoglycate in the treatment of asthma in children [abstract]. J Allergy Clin Immunol 1999;103 part 2. [Supp]:74.
39. Agertoft L, Pedersen S. Cost effectiveness of inhaled budesonide in children with chronic asthma [abstract]. Eur Respir J [Suppl] 1997;10:81.
40. Hall JR, Miocevich ML. Comparison of the cost effectiveness of salmeterol versus salbutamol in patients with moderate asthma [abstract]. Thorax 1992;47:883.
41. Barnes PJ, Thwaites RMA, Price MJ. The cost-effectiveness of inhaled fluticasone propionate and budesonide in the treatment of asthma in adults and children. Respir Med 1999;93:402-407.
42. Tierce JC, Meller W, Berlow B, Gerth WC. Assessing the cost of albuterol inhalers in the Michigan and California Medicaid programs: A total cost-of-care approach. Clin Ther 1989;11:53- 61.
43. Bernard-Bonnin AC, Stachenko S, Bonin D, Charette C, Rousseau E. Self-management teaching programs and morbidity of paediatric asthma: A meta-analysis. J Allergy Clin Immunol 1995;95:34-41.
44. Ram F, Robinson S, Black P. Physical training for asthma. Cochrane Database Syst Rev 2000. Issue 4.
45. Clark NM, Feldman CH, Evans D, Levison MJ, Wasilewski Y, Mellins RB. The impact of health education on frequency and cost of health care use by low income children with asthma. J Allergy Clin Immunol 1986;78:108-115.
46. Weinstein AG, McKee L, Stapleford J, Faust D. An economic evaluation of short term inpatient rehabilitation for children with severe asthma. J Allergy Clin Immunol 1996;98:264-273.
47. Ronchetti R, Indinnimeo L, Bonci E, Corrias A, Evans D, Hindi-Alexander M, Midulla F, Pulejo R, Villa MP. Asthma self-management programmes in a population of Italian children: a multicentric study. Italian Study Group on Asthma Self- Management Programmes. Eur Respir J 1997;10:1248-1253.
48. Eastwood AJ, Sheldon TA. Organization of asthma care: What difference does it make? A systematic review of the literature. Qual Health Care 1996;5:134-143.
49. Bartter T, Pratter MR. Asthma: better outcome at lower cost? The role of the expert in the care system. Chest 1996;110:1589-1596.
50. Nyman JA, Hillson S, Stoner T, de Vries A. Do specialists order too many tests? The case of allergists and pediatric asthma. Ann Allergy Asthma Immunol 1997;79:496-502.
51. Bryce FP, Neville RG, Crombie IK, Clark RA, McKenzie P. Controlled trial of an audit facilitator in diagnosis and treatment of childhood asthma in general practice. Br Med J [Clin Res] 1995;310:838-842.
52. McCowan C, Neville RG, Crombie IK, Clark RA, Warner FC. The facilitator effect: Results from a four-year follow-up of children with asthma. Br J Gen Pract 1997;47:156-160.
53. Greineder DK, Loane KC, Parks P. Reduction in resource utilization by an asthma outreach program. Arch Pediatr Adolesc Med 1995;149:415-420.
54. Greineder DK, Loane KC, Parks P. A randomized controlled trial of a pediatric asthma outreach program. J Allergy Clin Immunol 1999;103:436-440.
55. Kelly CS, Morrow AL, Shults J, Nakas N, Strope GL, Adelman RD. Outcomes evaluation of a comprehensive intervention program for asthmatic children enrolled in Medicaid. Pediatrics 2000;105:1029-1035.
56. Bender B, Milgrom H, Rand C. Nonadherence in asthmatic patients: Is there a solution to the problem? Ann Allergy Asthma Immunol 1997;79:177-186.
57. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. Oxford: Oxford University Press; 1996. p 392-411.